Group 1 - The fourth session of the Supervisory Board of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. was held on July 11, 2025, with all three supervisors present [1][2] - The Supervisory Board approved the adjustment of the price related to the 2023 restricted stock and stock option incentive plan, in compliance with relevant laws and regulations [1][2] - The decision to cancel part of the restricted stock and revoke some stock options was also approved, ensuring no substantial impact on the company's financial status or operational results [2] Group 2 - The voting results showed unanimous support with 3 votes in favor, and no votes against or abstentions [2] - The adjustments made do not require submission to the shareholders' meeting as authorized by the first temporary shareholders' meeting of 2024 [1][2]

Meeting Information - The company will hold its second extraordinary general meeting of shareholders in 2025 on July 28, 2025, at 14:30 [1] - Network voting will also take place on the same day, with specific time slots for voting through the Shenzhen Stock Exchange trading system and internet voting system [1] Voting Procedures - Shareholders can choose either on-site voting or network voting, but not both; if duplicate votes are cast, the first vote will be considered valid [2] - Only ordinary shareholders registered by the cut-off date are eligible to attend and vote, and they may appoint proxies to represent them [2][4] Agenda Items - The meeting will discuss several proposals, including adjustments to the board of directors and amendments to the company's articles of association [3][4] - Certain proposals require a special resolution, needing more than two-thirds of the voting rights held by attending shareholders, while others require a simple majority [4] Registration and Attendance - Registration for the meeting will occur on July 25, 2025, with specific times and location provided for shareholders to complete the registration process [5] - Attendees must bring relevant identification documents for registration [5] Voting Process - The voting will be non-cumulative, and shareholders can express their opinions as agree, disagree, or abstain [6] - Detailed procedures for voting through the Shenzhen Stock Exchange systems are provided, including identity verification requirements [6]

Group 1 - The company has nominated Ms. Jiang Qian as a candidate for the fourth board of directors as a non-independent director, pending approval at the upcoming shareholders' meeting [1][2] - The company plans to add one employee representative director to enhance its corporate governance structure, which is in compliance with relevant laws and regulations [1][2] - The election of Mr. Liu Gaofeng as the employee representative director has been approved by the employee representative assembly, with his term starting upon the approval of the relevant proposals at the shareholders' meeting [2] Group 2 - Ms. Jiang Qian, born in March 1988, has no overseas permanent residency and holds a bachelor's degree; she has previously worked at Yongqing Environmental Protection Co., Ltd. and is currently the secretary of the board [2][3] - Mr. Liu Gaofeng, born in June 1980, also has no overseas permanent residency and holds a bachelor's degree; he has served as a business manager at Amgen Shanghai and is currently the general manager of Hunan Dajia Weikang Pharmaceutical Co., Ltd. [4] - Both candidates do not hold shares in the company and have no related party relationships with major shareholders or other board members, ensuring compliance with legal requirements for board membership [3][4]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.'s adjustments to its 2023 restricted stock and stock option incentive plan, including the cancellation of certain stocks and options, comply with relevant laws and regulations [1][8]. Group 1: Approval and Authorization - The adjustments, cancellations, and authorizations related to the incentive plan were approved by the company's board and do not require further shareholder approval [4][6]. - The legal opinion asserts that necessary approvals and authorizations have been obtained, aligning with the Management Measures and the company's articles of association [8]. Group 2: Price Adjustment Details - The company will distribute a cash dividend of RMB 0.818 per share, totaling RMB 16,801,981.76, based on a total share capital of 205,403,200 shares as of December 31, 2024 [4][5]. - The adjusted grant price for the second category of restricted stock is set at RMB 6.7982 per share, down from RMB 6.88, while the stock option exercise price is adjusted to RMB 13.6782 per share from RMB 13.76 [5][6]. Group 3: Cancellations of Stocks and Options - A total of 120,000 shares of restricted stock and 280,000 stock options will be canceled due to the departure of four incentive targets, reducing the number of eligible participants from 33 to 29 [6][8]. - If the company's performance targets are not met, additional stocks and options will be canceled, with 576,000 shares and 1,344,000 options potentially affected [7][8].

Core Viewpoint - The company announced the cancellation of certain restricted stocks and the termination of stock options as part of its 2023 incentive plan due to the departure of four incentive recipients, which has been approved through the necessary procedures [1][3][6] Summary by Sections Approval Procedures - The company has completed the necessary approval processes for the incentive plan, including the review and verification by the supervisory board [1][2] Cancellation and Termination Details - A total of 4 individuals who were part of the incentive plan have left the company, leading to the cancellation of 45,600 shares of restricted stock and the termination of 1,064,000 stock options that were not yet vested [3][5] Impact on Financials and Operations - The cancellation of the unvested restricted stocks and the termination of stock options will not have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the continuation of the incentive plan [5][6] Opinions from Committees - The Compensation and Assessment Committee supports the cancellation and termination actions, stating they comply with relevant regulations and the incentive plan [5][6] Legal Compliance - The legal opinion confirms that the actions taken regarding the cancellation and termination of stocks and options have received the necessary approvals and comply with applicable laws and regulations [6]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-044 湖南达嘉维康医药产业股份有限公司 关于 2023 年限制性股票与股票期权激励计划作废部分第二类 限制性股票及注销部分股票期权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日召开第四届董事会第十五次会议、第四届监事会第十二次会议，审议通过 了《关于 2023 年限制性股票与股票期权激励计划作废部分第二类限制性股票及 注销部分股票期权的议案》，现将相关事项公告如下： 一、本次激励计划已履行的相关审批程序 1、2023 年 12 月 26 日，公司召开第四届董事会第三次会议和第四届监事会 第三次会议审议通过了《关于公司<2023 年限制性股票与股票期权激励计划（草 案）>及其摘要的议案》、《关于公司<2023 年限制性股票与股票期权激励计划 实施考核管理办法>的议案》、《关于提请股东会授权董事会办理公司 2023 年限 制性股票与股票期权激励计划相关事宜的议案》等议案，公司监事会对本激励计 划的相关事项 ...

湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 致：湖南达嘉维康医药产业股份有限公司 湖南启元律师事务所（以下简称"启元"或"本所"）接受湖南达嘉维康医 药产业股份有限公司（以下简称"达嘉维康""公司"或"上市公司"）的委托， 担任达嘉维康 2023 年限制性股票与股票期权激励计划（以下简称"本次激励计 划""本激励计划"或"激励计划"）的专项法律顾问。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理 办法》（以下简称"《管理办法》"）等现行法律、法规和规范性文件的有关规 定以及《湖南达嘉维康医药产业股份有限公司章程》（以下简称"《公司章程》"）、 《湖南达嘉维康医药产业股份有限公司 2023 年限制性股票与股票期权激励计划 （草案）》（以下简称"《激励计划（草案）》"），按照律师行业公认的业务 标准、道德规范和勤勉尽责精神，现就公司 2023 年限制性股票与股票期权激励计 划 ...

湖南达嘉维康医药产业股份有限公司 内幕信息知情人登记制度 （2025 年 7 月修订） 第一章 总则 1 第二章 内幕信息的范围 可能对公司的股票交易价格产生较大影响的重大事件: 可能对公司债券的交易价格产生较大影响的重大事件: (1) 公司股权结构或者生产经营状况发生重大变化; 2 第六条 本制度所指内幕信息是指涉及公司的经营、财务或者对公司证券及其衍生品 种的市场价格有重大影响的尚未公开的信息。尚未公开是指公司尚未在《公 司章程》指定的信息披露刊物或网站上正式公开披露。 第七条 本制度所指内幕信息的范围包括但不限于: 第一条 为加强湖南达嘉维康医药产业股份有限公司(以下简称"公司")内幕信息管 理, 做好内幕信息保密工作, 维护信息披露的公平原则, 保护广大投资者的 合法权益, 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司信息披露管理办法》《深圳证券交易所创业板股票上市规则》《上市公司 监管指引第 5 号——上市公司内幕信息知情人登记管理制度》等有关法律、 法规、规范性文件及《湖南达嘉维康医药产业股份有限公司章程》(以下简称 "《公司章程》")的有关规定, 结合公司实际情况, 特制定本 ...

湖南达嘉维康医药产业股份有限公司 独立董事工作制度 （2025 年 7 月修订） 第一章 总则 独立董事应当按照相关法律、行政法规和中国证监会规定、证券交易所业务规则 和《公司章程》的规定, 认真履行职责, 在董事会中发挥参与决策、监督制衡、 专业咨询作用, 维护公司整体利益, 保护中小股东合法权益。 (八) 法律、行政法规、中国证监会规定、证券交易所业务规则和《公司章程》 规定的不具备独立性的其他人员。 本条第一款中的"附属企业"是指受相关主体直接或者间接控制的企业; "主要 社会关系"是指兄弟姐妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子 女的配偶、子女配偶的父母等; "重大业务往来"是指根据《深圳证券交易所创 业板上市规则》及深圳证券交易所相关规定或《公司章程》规定需提交股东会审 议的事项, 或者深圳证券交易所认定的其他重大事项; "任职"是指担任董事、 监事、高级管理人员以及其他工作人员。 独立董事应当每年对独立性情况进行自查,并将自查情况提交董事会。董事会应 当每年对在任独立董事独立性情况进行评估并出具专项意见, 与年度报告同时 披露。 独立董事应当独立履行职责, 不受公司主要股东、实际控制人 ...

湖南达嘉维康医药产业股份有限公司 内部审计制度 第二章 内部审计部的设立 第三章 内部审计职责 2 第七条 公司董事会下设审计委员会, 制定审计委员会工作细则并予以披露。审计委员会成 员全部由董事组成, 其中独立董事应占半数以上, 且至少应有一名独立董事为会计 专业人士并由其担任召集人。 第八条 公司设立内部审计部, 在公司董事会审计委员会领导下, 负责公司内部审计工作, 依据国家法律、法规、部门规章和规范性文件及《公司章程》, 独立行使内部审计 监督权, 对审计委员会负责并报告工作。 第九条 公司内部审计部配置专职人员从事内部审计工作, 且专职人员应不少于三人。 第十条 内部审计部设内部审计部负责人一名, 由审计委员会提名, 董事会任免。 第十一条 内部审计部应当保持独立性, 不得置于财务部门的领导之下, 或者与财务部门合署 办公。 第十二条 公司各内部机构或者职能部门、控股子公司以及对公司具有重大影响的参股公司应 当配合内部审计部依法履行职责，不得妨碍内部审计部的工作。 （2025 年 7 月修订） 第一章 总则 1 第一条 为加强湖南达嘉维康医药产业股份有限公司(以下简称"公司")内部审计工作, 提 高 ...